Opinion|Videos|October 21, 2024
Factors Impacting Use of HER2 Therapies for NSCLC
Key Takeaways
- Barriers to HER2-directed therapies include high costs, limited insurance coverage, and stringent prior authorization requirements, impacting patient access and treatment initiation.
- Providers prioritize clinical outcomes like progression-free survival and overall response rates, which may not align with payer focus on cost-effectiveness.
Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Analyze payer perspectives and access challenges related to HER2-directed therapies in NSCLC.
- (Kim) What are potential barriers to starting and/or persisting on HER2-directed therapies for NSCLC?
- (Bazhenova) Which outcomes do providers find most important in clinical practice, and how do these align with the outcomes payers prioritize when assessing the value of these therapies?
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5